IMVT
Immunovant, Inc. · Healthcare
Chief Development Officer Julia G. Butchko sold $78K of Immunovant, Inc.
Sold$77,578
$36.15Price
2,146Shares
−1%Stake
What IMVT did after the filing
- The stock from Fri, Feb 23 close, $37.00
- −17.5%
- S&P 500, same days
- +2.5%
Measured over 30 trading days, to the Apr 8 close.
Traded Thu, Feb 22. Filed Fri, Feb 23, 11:14 AM ET, during the session. Returns use the Feb 23 close and the Apr 8 close. Not investment advice.